BDX Stock Forecast & Price Target

Becton Dickinson is experiencing positive momentum with significant growth prospects, as evidenced by management's focus on volume-based procurement in China, which is set to cover 80% of its portfolio by the end of 2026, driving continued volume growth in the region. The company is also entering the Biosurgery market, valued at nearly $400 million and projected to grow at approximately 5%, further enhancing its market position. Additionally, BD Connected Care has reported $1.13 billion in sales, reflecting a year-over-year increase of 4.7% when excluding foreign exchange effects, underscoring the strong performance in critical product segments.

Becton Dickinson is facing several challenges that contribute to a negative outlook on its stock, primarily due to weak revenue growth projections and market dynamics that impact its Chinese operations. The company's commitment to reducing leverage from approximately 3x to 2.5x over the next 12-18 months may constrain financial flexibility, while performance in its product segments, particularly the decline in Alaris revenue, adds further pressure. Additionally, anticipated headwinds from ongoing remediation efforts, declining lifesciences research funding, and potential tariff impacts are expected to create significant margin pressures that complicate the pathway to meaningful earnings per share growth.